GTX Inc. (NASDAQ: GTXI) is stronger Thursday after Jefferies reiterated its Buy rating and boosted its price target from $6 to $8 following the company's presentation at the Jefferies 2013 Global Healthcare Conference.

Analyst Biren Amin weighs in: "At our annual healthcare conference, Mitchell Steiner, CEO, provided an updated on the ongoing POWER PIII trials and is expecting last patient out in both trials by end-May with topline data in Q3 ’13 (JEF est: July). The topline data release should incl 3-mo co-primary endpts, 2 EP - durability of resp, and an OS update. We continue to believe on a favorable POWER outlook with the EU opportunity as upside."

For an analyst ratings summary and ratings history on GTX Inc. click here. For more ratings news on GTX Inc. click here.